Ruxolitinib in Treating Participants With Chronic Myeloid Leukemia With Minimal Residual Disease While on Therapy With Tyrosine Kinase Inhibitors
M.D. Anderson Cancer Center
M.D. Anderson Cancer Center
Novartis
OHSU Knight Cancer Institute
Sumitomo Pharma America, Inc.
Dana-Farber Cancer Institute
M.D. Anderson Cancer Center
Novartis
Novartis
Bristol-Myers Squibb
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.
Dong-A ST Co., Ltd.
City of Hope Medical Center
Children's Oncology Group
University of Rochester
Barbara Ann Karmanos Cancer Institute
The Cleveland Clinic
National Cancer Institute (NCI)
Chong Kun Dang Pharmaceutical
M.D. Anderson Cancer Center
Novartis